Screener
Summit Therapeutics SMMT Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Oncology clinical trial related costs | $90,195 | $36,363 |
| Compensation related costs, excluding stock-based compensation | 26,432 | 15,854 |
| Stock-based compensation | 72,791 | 11,096 |
| Other expenses (1) | 5,794 | 3,538 |
| Total segment expenses | 195,212 | 66,851 |
| Other income, net | 5,788 | 3,938 |
| Net loss | $(189,424) | $(62,913) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's business segments — stock-based comp?
- Summit Therapeutics (SMMT) reported business segments — stock-based comp of $72.79M in Q1 2026.
- How has Summit Therapeutics's business segments — stock-based comp changed year-over-year?
- Summit Therapeutics's business segments — stock-based comp increased by 556.0% year-over-year, from $11.1M to $72.79M.
- What is the long-term trend for Summit Therapeutics's business segments — stock-based comp?
- Over 3 years (2022 to 2025), Summit Therapeutics's business segments — stock-based comp has grown at a 294.3% compound annual growth rate (CAGR), from $11.95M to $732.42M.
- What does business segments — stock-based comp mean?
- Represents the non-cash expense recognized for equity-based awards granted to employees and directors within the segment. This reflects the cost of using stock options or restricted stock units as a form of compensation.
Ask your AI about Summit Therapeutics's business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude